Hua Medicine
IPOGlobal innovation in diabetes care.
Hua Medicine was founded in 2010, is headquartered in Shanghai, China, lists 51–200 employees, and has $212.5M in recorded funding across 4 rounds.
- Headquarters
- Shanghai
- Employees
- 51–200
- Founded
- 2010
- Business Model
- B2B
- Website
- huamedicine.com
- Total Funding
- $212.5M
- Last Round
- $117.4M Series DMar 2018
- Rounds
- 4
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 4 funding rounds and 9 investors for this company. The full record is or through the API.
About
Hua Medicine is a clinical-stage biotech company focused on innovative therapies for type 2 diabetes and CNS disorders. Its lead product, HuaTangNing (dorzagliatin), a first-in-class glucokinase activator, was approved in China in 2022 for T2D patients, including those with renal impairment.
Summary
Hua Medicine is a Biotech company based in Shanghai, China, founded in 2010. It lists 51–200 employees. It has raised $212.5M in total across 4 rounds, most recently a $117.4M Series D round in Mar 2018. Investors include ARCH Venture Partners, Venrock and Blue Pool Capital.
Funding & Exit History
Sep 2018
Sign up to see all 5 events
Funding: Series A through Series D. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/hua-medicine"><img src="https://indexed.vc/api/badge/company/hua-medicine" alt="Hua Medicine on Indexed.vc" width="260" height="76" /></a>